Cargando…

Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion

Pathological sodium-water retention or edema/congestion is a primary cause of heart failure (HF) decompensation, clinical symptoms, hospitalization, reduced quality of life, and premature mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) based therapies reduce hospitalization due to HF,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hernandez, Michelle, Sullivan, Ryan D., McCune, Mariana E., Reed, Guy L., Gladysheva, Inna P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024630/ https://www.ncbi.nlm.nih.gov/pubmed/35454037 http://dx.doi.org/10.3390/diagnostics12040989

Ejemplares similares

Suppression of Cardiogenic Edema with Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Insights from Pre-Clinical Studies
por: Sullivan, Ryan D., et al.
Publicado: (2022)

Editorial: Edema in heart failure with reduced ejection fraction
por: Gladysheva, Inna P., et al.
Publicado: (2023)

Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction
por: Arslan, Kadem, et al.
Publicado: (2022)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
por: Pandey, Arjun K., et al.
Publicado: (2022)

Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction
por: Abdelhamid, Magdy, et al.
Publicado: (2022)

A Low-Sodium Diet Boosts Ang (1–7) Production and NO-cGMP Bioavailability to Reduce Edema and Enhance Survival in Experimental Heart Failure
por: Tripathi, Ranjana, et al.
Publicado: (2021)

The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction
por: Correale, Michele, et al.
Publicado: (2023)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
por: Brust-Sisti, Lindsay, et al.
Publicado: (2022)

Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction
por: Elserafy, Ahmed S., et al.
Publicado: (2021)

Cardiac-Specific Overexpression of Catalytically Inactive Corin Reduces Edema, Contractile Dysfunction, and Death in Mice with Dilated Cardiomyopathy
por: Tripathi, Ranjana, et al.
Publicado: (2019)

Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2021)

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
por: Cavka, Luka, et al.
Publicado: (2021)

Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction
por: Chiorescu, Roxana Mihaela, et al.
Publicado: (2022)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction
por: Jearath, Vaneet, et al.
Publicado: (2016)

Soluble (Pro)Renin Receptor Levels Are Regulated by Plasma Renin Activity and Correlated with Edema in Mice and Humans with HFrEF
por: Gladysheva, Inna P., et al.
Publicado: (2022)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
por: Takatsuna, Yoko, et al.
Publicado: (2020)

Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis
por: Glover, Sarah, et al.
Publicado: (2022)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2023)

Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival
por: Sullivan, Ryan D., et al.
Publicado: (2019)

Renin Activity in Heart Failure with Reduced Systolic Function—New Insights
por: Sullivan, Ryan D., et al.
Publicado: (2019)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Fukuta, Hidekatsu, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
por: Shen, Xizi, et al.
Publicado: (2022)

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction
por: Nonin, Shinichi, et al.
Publicado: (2018)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
por: Feng, Bin, et al.
Publicado: (2023)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
por: Sfairopoulos, Dimitrios, et al.
Publicado: (2022)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides
por: Silva Enciso, J.
Publicado: (2020)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
por: Li, Runmin, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
por: Chiba, Koki, et al.
Publicado: (2020)

Medical Treatment in Heart Failure with Reduced Ejection Fraction: A Proposed Algorithm Based on the Patient’s Electrolytes and Congestion Status
por: Paraskevaidis, Ioannis, et al.
Publicado: (2023)

Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction　― Novel Prospective Cohort Study ―
por: Sakai, Takaaki, et al.
Publicado: (2019)

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhou, Hufang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b77e3907727igicgqo85a1pbqt